Impact BioMedical Inc.
IBOHealthcare|Biotechnology|US
$4.11
-0.29 (-6.59%)
Graham Number
$1.62
Cash / Share
$0.00
Financials
Financial Snapshot
Market Cap
$35.5M
Enterprise Value
$35.5M
Revenue (TTM)
$35.0K
Net Income (TTM)
$789.0K
Cash & Investments
$10.0K
Net Cash
$10.0K
Free Cash Flow (TTM)
-$508.0K
Operating CF (TTM)
-$508.0K
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$10.0K
Quarterly Burn
$127.0K
Monthly Burn
$42.3K
Est. Runway
~0.1 quarters
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $72.3K | $46.0K | $2.0K | $1.0K | $2.0M | $3.0K | $10.0K | |
| Operating Cash Flow | -$898.5K | -$2.2M | -$2.2M | -$2.9M | -$5.6M | -$1.9M | -$508.0K | |
| Free Cash Flow | -$898.5K | -$2.5M | -$2.5M | -$2.9M | -$5.6M | -$1.9M | -$508.0K | |
| Capital Expenditure | $3.00 | -$276.0K | -$276.0K | -$18.0K | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $1.5M | $2.5M | $2.5M | $2.9M | $8.5M | -$109.0K | -$109.0K |
R&D Spending
R&D (TTM)
$284.0K
R&D Intensity
811.4%
R&D Growth vs Prior
-16.5%
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $50.0K | $50.0K | $0.00 | $0.00 | $32.0K | $35.0K | |
| R&D Expense | $513.7K | $1.2M | $1.2M | $1.7M | $278.0K | $340.0K | $284.0K | |
| R&D % of Revenue | — | 2452.0% | 2452.0% | — | — | 1062.5% | 811.4% | |
| SG&A | $383.0K | $1.0M | $1.0M | $1.1M | $1.8M | $2.0M | $3.0M |
Income Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $50.0K | $50.0K | $0.00 | $0.00 | $32.0K | $35.0K | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $424.0K | $424.0K | |
| Gross Profit | $0.00 | $50.0K | $50.0K | $0.00 | $0.00 | -$392.0K | -$389.0K | |
| R&D | $513.7K | $1.2M | $1.2M | $1.7M | $278.0K | $340.0K | $284.0K | |
| SG&A | $383.0K | $1.0M | $1.0M | $1.1M | $1.8M | $2.0M | $3.0M | |
| Operating Income | -$896.7K | -$3.4M | -$3.4M | -$4.0M | -$28.8M | -$4.3M | -$5.1M | |
| Interest Expense | $0.00 | $300.0K | $462.0K | $444.0K | $117.4K | $793.0K | $262.0K | |
| Pretax Income | -$896.7K | -$7.9M | -$7.9M | -$4.4M | -$24.7M | -$14.4M | -$1.8M | |
| Net Income | -$597.3K | -$7.1M | -$7.1M | -$4.3M | -$24.7M | -$11.8M | $789.0K | |
| EPS (Diluted) | -0.65 | -7.70 | -7.70 | -0.88 | -0.09 | -4.80 | -1.23 | |
| EBITDA | -$896.7K | -$6.3M | -$6.3M | -$2.8M | -$22.6M | -$12.5M | -$401.0K | |
| Shares Out. (M) | 0.91 | 0.91 | 0.91 | 4.77 | 3.31 | 2.50 | 8.54 |
Balance Sheet
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $72.3K | $46.0K | $2.0K | $1.0K | $2.0M | $3.0K | $10.0K | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $107.3K | $287.0K | $122.0K | $332.0K | $2.4M | $411.0K | $320.0K | |
| Total Assets | $48.1M | $56.4M | $46.5M | $44.6M | $20.3M | $17.4M | $16.7M | |
| Total Current Liabilities | $1.1M | $12.6M | $10.6M | $13.1M | $9.8M | $1.2M | $2.0M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $6.3M | $16.5M | $13.8M | $16.4M | $13.1M | $1.9M | $2.7M | |
| Stockholders' Equity | $37.9M | $36.6M | $29.6M | $25.2M | $4.3M | $12.6M | $10.8M | |
| Retained Earnings | -$271.2K | -$1.6M | -$8.6M | -$13.0M | -$37.7M | -$49.5M | -$52.5M |
Cash Flow Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$898.5K | -$2.2M | -$2.2M | -$2.9M | -$5.6M | -$1.9M | -$508.0K | |
| Capital Expenditure | $3.00 | -$276.0K | -$276.0K | -$18.0K | $0.00 | $0.00 | $0.00 | |
| Free Cash Flow | -$898.5K | -$2.5M | -$2.5M | -$2.9M | -$5.6M | -$1.9M | -$508.0K | |
| Investing Cash Flow | -$632.1K | -$349.0K | -$349.0K | -$15.0K | $2.9K | $3.0K | $3.0K | |
| Financing Cash Flow | $1.5M | $2.5M | $2.5M | $2.9M | $8.5M | -$109.0K | -$109.0K | |
| Issuance of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $5.4M | $0.00 | $0.00 | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $1.1M | $2.5M | $2.5M | $2.9M | $3.1M | -$109.0K | $373.0K | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $13.0K | $13.0K | |
| Net Change in Cash | $72.3K | -$44.0K | -$44.0K | -$1.0K | $2.9M | -$2.0M | -$614.0K |
Dilution Tracker
Shares outstanding grew 174.3% over 5 years — significant dilution
Shares Outstanding
9M
5-Year Share Growth
+174.3%
Stock Issuance (TTM)
$0.00
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.91 | 0.91 | 0.91 | 4.77 | 3.31 | 2.50 | 8.54 | |
| Change vs Prior % | — | 0.0% | -0.1% | 424.0% | -30.7% | -24.4% | 241.7% | |
| Stock Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $5.4M | $0.00 | $0.00 | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $13.0K | $13.0K |
Margins & Profitability
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | 100.0% | 100.0% | — | — | -1225.0% | -1111.4% | |
| Operating Margin % | — | -6808.0% | -6808.0% | — | — | -13343.8% | -14562.9% | |
| Net Margin % | — | -14102.0% | -14102.0% | — | — | -36993.8% | 2254.3% | |
| EBITDA Margin % | — | -12602.0% | -12602.0% | — | — | -39100.0% | -1145.7% | |
| FCF Margin % | — | -5036.0% | -5036.0% | — | — | -5906.3% | -1451.4% | |
| ROE % | -1.6% | -19.3% | -23.9% | -17.2% | -580.1% | -93.9% | 13.7% | |
| ROA % | -1.2% | -12.5% | -15.2% | -9.7% | -121.8% | -68.0% | 4.7% | |
| ROIC % | -1.7% | -5.6% | -6.8% | -9.2% | -148.3% | -21.6% | 14.9% | |
| R&D / Revenue % | — | 2452.0% | 2452.0% | — | — | 1062.5% | 811.4% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | -100.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | -100.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | -279.6% | 0.0% | -18.3% | -613.8% | 85.1% | |
| Net Income | 0.0% | -1080.4% | 0.0% | 38.5% | -469.8% | 52.1% | |
| EPS (Diluted) | 0.0% | -1075.3% | 0.0% | 88.5% | 90.1% | -5407.2% | |
| Operating Cash Flow | 0.0% | -149.5% | 0.0% | -27.2% | -97.7% | 66.5% | |
| Free Cash Flow | 0.0% | -180.2% | 0.0% | -13.9% | -96.4% | 66.5% | |
| R&D Expense | 0.0% | 138.7% | 0.0% | 37.4% | -83.5% | 22.3% | |
| SG&A Expense | 0.0% | 173.3% | 0.0% | 5.4% | 65.7% | 8.0% | |
| Total Assets | 0.0% | 17.3% | -17.6% | -4.0% | -54.5% | -14.2% | |
| Book Value / Share | 0.0% | -4.4% | -18.2% | -83.5% | -63.1% | 184.5% | |
| Debt | 0.0% | 1082.4% | -20.2% | 20.8% | -26.5% | -100.0% | |
| Diluted Shares | 0.0% | 0.0% | -0.1% | 424.0% | -30.7% | -24.4% |
Valuation
P/E (TTM)At Loss
P/S1014.58
10Y Low / Med / High497.66 / 616.25 / 616.25
P/B3.26
10Y Low / Med / High0.81 / 1.26 / 14.22
EV/EBITDAAt Loss
EV/Revenue1014.30
10Y Low / Med / High497.57 / 816.03 / 865.81
P/FCFAt Loss
Intrinsic Value Models (per share)
Graham Number
$1.62
Cash / Share
$0.00
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -51.64 | -4.39 | -4.39 | -38.28 | -210.16 | -1.33 | -3.34 | |
| P/S Ratio | 0.00 | 616.25 | 616.25 | 0.00 | 0.00 | 497.66 | 1014.58 | |
| P/B Ratio | 0.81 | 0.84 | 1.04 | 6.40 | 14.22 | 1.26 | 3.26 | |
| EV/EBITDA | -35.48 | -6.87 | -6.48 | -61.04 | -2.99 | -1.27 | -88.53 | |
| EV/Revenue | 0.00 | 865.81 | 816.03 | 0.00 | 0.00 | 497.57 | 1014.30 |
Analyst Estimates & Quality
Altman Z-Score
2.98
Grey Zone
Piotroski F-Score
4
Moderate